Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Brain Endothelium - TARgeted Gene therapy to improve Aβ clearance in Alzheimer’s Disease

BEndTarG

Alzheimer disease (AD) is the most common cause of dementia (60-80% of cases) with a prevalence near 50 million people. There is no cure available and there are only two classes of approved drugs that are effective in treat some of the cognitive symptoms and potentially delay the clinical decline. Despite the considerable progress achieved in the...

Funding Programme
Start Date
End Date
Total Funding
€ 165 312
European Countries Involved

Brain fluids - Transport and clearance

aCleanBrain

"Scientific breakthroughs in neuroscience explain the need for sleep and the development of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases in terms of fluid dynamics: the waste created during the day is cleared away as we sleep or it accumulates. However, a decade of research after the original theory was posed has revealed...

Funding Programme
Start Date
End Date
Total Funding
€ 2 493 750
European Countries Involved

Brain health in Atherosclerosis and Cardiovascular risk in mid-life, a PESA-Brain project

BrainAtCardio

This project aims to investigate the early associations between cardiovascular health and Alzheimers disease (AD) pathology, with a focus on subclinical atherosclerosis (SCAth) and cardiovascular risk factors (CVRFs), in a large cohort of asymptomatic, middle-aged individuals. The overarching objective is to determine how cardiovascular health in...

Funding Programme
Start Date
End Date
Total Funding
€ 194 074
European Countries Involved

Brain image processing with Alpha-Stable distributions. Applications to intensity normalization,segmentation and diagnosis of Parkinsonian syndrome and Alzheimer's disease

ALPHA-BRAIN-IMAGING

In this project, D. Salas-Gonzalez proposes to develop brain image processing with alpha-stable distributions with applications to intensity normalization, segmentation and diagnosis of Parkinsonian syndrome and Alzheimer's disease. The expected results of this interdisciplinary project will definitely have applications and impact in the European...

Funding Programme
Start Date
End Date
Total Funding
€ 223 778
European Countries Involved

BRain Imaging, cognition, Dementia and next generation GEnomics: a Transdisciplinary approach to search for risk and protective factors of neurodegenerative disease

BRIDGET

Establishing efficient prevention strategies for dementia and Alzheimer's disease is a major health priority. Since the cascade of events leading to Alzheimer's disease begins many years before the disease is detected, efficient prevention should be initiated early.

This requires identifying individuals in the general population who are at high...

Funding Programme
Start Date
End Date
Total Funding
€ 3 111 460
European Countries Involved

Brain Microcirculation : Numerical simulation for inter-species translation with applications in human health

BrainMicroFlow

The cerebral microvascular system is essential to a large variety of physiological processes in the brain, including blood delivery and blood flow regulation as a function of neuronal activity (neuro-vascular coupling). It plays a major role in the associated mechanisms leading to disease (stroke, neurodegenerative diseases, …). In the last decade...

Funding Programme
Start Date
End Date
Total Funding
€ 1 999 873
European Countries Involved

BrainQ, non-invasive, very low intensity, BCI-based frequency dependent electromagnetic field tailored treatment for neuro recovery (BQ).

BQ-Technology

The WHO has identified neurological disorders as a major burden and emerging challenge to global healthcare systems. These range from causes such as stroke and dementia, to injuries and viral infections. The prevalence of strokes and dementia are strongly linked to increasing age, for example stroke risk more than doubles every decade after 55...

Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

Bridging the world of fungi and dementia

PROFITS

Alzheimer’s disease is the most common form of dementia which seriously interferes with the daily life of millions of people. People suffering from Alzheimer’s disease show the accumulation of two misfolded proteins in the nerve cells of their brains – amyloid plaques and tau tangles. Although many aspects of the Alzheimer’s disease pattern are...

Funding Programme
Start Date
End Date
Total Funding
€ 100 000
European Countries Involved

Building Next-Generation Brain/Neural-Machine Interfaces For Restoration of Brain Functions

NGBMI

Today, five out of ten diseases worldwide resulting in long-term disability are related to the central nervous system. Due to the immense complexity and inter-individual variability of the human mind and brain there are still no effective and side effect free treatment options for many serious neuropsychiatric disorders, such as major depression...

Funding Programme
Start Date
End Date
Total Funding
€ 1 498 125
European Countries Involved

C9orf72 repeat expansion in FTD/ALS - from mechanisms to therapeutic approaches

DPR-MODELS

Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are fatal neurodegenerative diseases with overlapping genetics and pathology. The most common known cause is expansion of a GGGGCC repeat in the first intron of the gene C9orf72. I discovered that the repeat region is translated in all three reading frames into aggregating...

Funding Programme
Start Date
End Date
Total Funding
€ 1 991 000
European Countries Involved

C9orf72-mediated neurodegeneration: mechanisms and therapeutics

C9ND

An expanded GGGGCC repeat in a non-coding region of the C9orf72 gene is the most common known cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The repeat RNA is transcribed and accumulates in neuronal RNA aggregates, implicating RNA toxicity as a key pathogenic mechanism. However, the pathways that lead to...

Funding Programme
Start Date
End Date
Total Funding
€ 1 985 699
European Countries Involved

Calcium-Sensing Receptor (CaSR): Therapeutics for Non-Communicable Diseases

CaSR Biomedicine

The calcium sensing receptor (CaSR) is a class C Gprotein-coupled receptor that plays a pivotal role in systemic calcium metabolism by regulating parathyroid hormone secretion and urinary Ca excretion. Abnormal CaSR function is implicated in calciotropic disorders, and in non-calciotropic disorders such as Alzheimer’s disease (AD), cardiovascular...

Funding Programme
Start Date
End Date
Total Funding
€ 3 657 195
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).